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Abstract
The nuclear factor-kappa B (NF-κB) transcription factor plays an essential role in the host immune response to
different pathogens and genotoxic stimuli. In addition and either dependently or independently, it also promotes
malignant transformation. The first step in its activation is conversion of extracellular stimuli to a cascade of
reactions mediated by a variety of membrane receptors. The activated receptor transmits the signal through
downstream proteins to activate different kinases. Subsequently, the inhibitory proteins that sequester NF-κB in the
cytoplasm are phosphorylated, ubiquitinated, and degraded in the proteasome. Free NF-κB then enters the nucleus
to initiate its transcriptional program. An important signaling “code” in the multiple-step NF-κB activating cascade
consists of different ubiquitin (Ub) chains that are assembled on the different effector proteins through different
lysine residues in the Ub molecule. Together with this unique set of proteins in the cascade, Ub chains form the
platform for the binding of downstream interacting partners. One unknown link in the activation of NF-κB was the
ubiquitin ligase that catalyzes generation of the active p50 subunit from its p105 inactive precursor. We found that
KPC1 ubiquitinates p105 and catalyzes its processing to p50 under both basal and signal-induced conditions. A
variety of biological functions carried out by NF-κB, depends on the dimeric composition of the transcription factor,
and can determine the tumor suppression/promotion fate of the cell. Overexpression of KPC1 probably shifts the
balance between NF-κB subunits from the “canonical” p50·p65 heterodimer to a p50 homodimer which results in a
strong tumor suppressive phenotype.
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Review
A leading role in regulating essential cellular processes
such as proliferation, differentiation, cell survival, and
immune response is carried out by the family of NF-κB
transcription factors. The involvement of malfunction
within the NF-κB pathway in the development of
chronic inflammation and subsequent malignant trans-
formation has recently become a scientific certainty
(Ben-Neriah and Karin, 2011; DiDonato et al., 2012).
The NF-κB pathway depends in many of its steps on
ubiquitination. Ubiquitin (Ub) is a small, 76 amino acid
protein that can modify a variety of proteins. The reac-
tion is catalyzed by three types of enzymes that act in
concert: E1, a Ub activating enzyme; E2, a Ub conjugat-
ing enzyme (or Ub carrier protein); and E3, a substrate-
specific Ub ligase. As a result, the C-terminal Gly of Ub
is typically conjugated covalently to the ε-amino group
of an internal lysine residue(s) in the target substrate
(Glickman and Ciechanover, 2002). In many cases, the
substrate is modified by a chain that is composed of Ubs
bound to each other through internal lysine residues
(K6, K11, K27, K29, K33, K48, and K63) in the Ub mol-
ecule. Sometimes the Ub molecules are linked “head-to-
tail” with the C-terminus of Ub conjugated via peptide
bond to the α-amino group of the first methionine of
the previous Ub, resulting in generation of linear chains.
Different linkages of the Ub chain have distinct structure
and therefore modulate, via different interactions a var-
iety of cellular processes such as proteasomal degrad-
ation, signal transduction, or specific cellular localization
(Komander and Rape, 2012).
The activation of NF-κB starts in many cases with the
recognition and binding of different pro-inflammatory
cytokines by specific cell membrane receptors. Tumor
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necrosis factor alpha (TNFα), lipopolysaccharide (LPS),
interleukin-1 beta (IL-1β), and cluster of differentiation
40 (CD40L) are examples of proteins that can activate
NF-κB (Rahman and McFadden, 2011). In general, there
are two types of NF-κB activation—“canonical” and “al-
ternative.” They differ in the cascade of adaptor proteins
downstream of the receptor, in subsequent activation of
different kinases, and in generation of transcription fac-
tors that possess different subunits. Despite the differ-
ence, all the pathways have a similar scheme: ligand,
specific receptor, and cascade of adaptor proteins (modi-
fied by Ub chains that serve a non-proteolytic function).
These proteins “translate” the activation of the receptor to
activation of a distinct kinase, modification of the inhibi-
tory protein by Ub chains that leads to its proteasomal
destruction with subsequent formation of active NF-κB
that is translocated into the nucleus.
In this review, we shall focus on one particular ex-
ample of TNFα-induced NF-κB activation pathway
(Fig. 1).
The ligand protein TNFα is one of the most important
inflammatory cytokines. It leads to the activation of NF-
κB through the canonical pathway. A trimer of the
extracellular transmembrane tumor necrosis factor re-
ceptor 1 (TNFR1) specifically recognizes a trimeric
TNFα (Idriss and Naismith, 2000). In its bound state,
the receptor interacts with the TNF receptor-associated
protein with death domain (TRADD) (Hsu et al., 1995).
The complex includes also the receptor-interacting
protein-1 (RIP1) kinase, that is essential for TNF-
Fig. 1 The multi-step activation pathway of the NF-κB transcription factor. For details, see the main text. Yellow circles denote Ub48-linked chains.
Orange circles denote K64-based chains. Blue circles denote linear Ub chains. The yellow arrow denotes ubiquitination. The green arrow denotes
de-ubiquitination. The red arrow denotes phosphorylation
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dependent NF-κB activation independently of its kinase
function (Kelliher et al., 1998). Following TNFα signal-
ing, RIP1 is ubiquitinated by several ubiquitin ligases.
TNF receptor-associated factor (TRAF2) (Lee et al.,
2004) and cellular inhibitor of apoptosis-1 and
apoptosis-2 (cIAP1 and cIAP2) (Bertrand et al., 2008;
Park et al., 2004) modify RIP1 by K63-linked ubiquitin
chains. The ubiquitination that occurs on K377 of RIP1
(Ea et al., 2006) serves as a platform for the binding of
TAK1-binding protein (TAB)-TAK1-complex (Kanayama
et al., 2004), as well as NF-κB essential modulator
NEMO (Ea et al., 2006; Wu et al., 2006). This event pro-
motes activation of IκB kinase (IKKα/β) with subsequent
phosphorylation, ubiquitination, and degradation of IκB
inhibitory proteins. Prior to their degradation, the IκB
proteins retain NF-κB dimers in the cytoplasm.
The ubiquitin ligase cIAP1 along with the ubiquitin
conjugation enzyme UbcH5 catalyzes yet another conju-
gation reaction—generation of K11-linked ubiquitin
chains on RIP1. The resulting ubiquitin chain(s) have a
structure that could be recognized by NEMO (Dynek
et al., 2010).
To regulate the process, the dual function tumor ne-
crosis factor alpha-induced protein 3 (A20) (that pos-
sesses both a deubiquitinating (DUB) and a K48
ubiquitin ligase activities) modifies RIP1 by removing
the K63 chain and generating a K48-based chain, leading
to destruction of the protein, thus attenuating the TNFα
signal (Wertz et al., 2004).
Finally, linear ubiquitin chains were also described as
an important regulatory signal in the inflammatory re-
sponse and NF-κB activation. The linear Ub chain as-
sembly complex (LUBAC) is a unique ligase that is able
to synthetize linear Ub chains (Kirisako et al., 2006).
LUBAC is made of the heme-oxidized IRP2 ligase-1
(HOIL-1L), HOIL-1L-interacting protein (HOIP), and
SHANK-associated RH domain interacting protein
(SHARPIN). HOIP is a catalytic subunit that through its
Ub-associated (UbA) domain binds to Ub-like (UbL) do-
mains of HOIL-1L and SHARPIN (Yagi et al., 2012).
Linear Ub chains can serve as the platform for recruit-
ment of NEMO through UBAN (Ub binding in ABIN
and NEMO) domain (Rahighi et al., 2009). Alternatively,
NEMO itself can be modified by linear ubiquitin chains
on the specific Lys residues in the CC2-LZ domain
(Tokunaga et al., 2009). In both cases, the result is
TNFα-induced activation of the IKK complex (Iwai
et al., 2014).
Active NF-κB transcription factor is a family of dimers,
the members of which are made of different proteins in
different combinations, including p50 (derived from pro-
cessing of p105—NF-κB1) (Fan and Maniatis, 1991;
Palombella et al., 1994), p52 (derived from processing of
p100—NF-κB2) (Betts and Nabel, 1996), p65 (RelA),
RelB, and c-Rel. All of them have a REL homology do-
main (RHD) that binds DNA. The NF-κB subunits form
homo- or heterodimers that in resting cells stay in the
cytoplasm bound to the ankyrin repeats of IκB inhibitory
proteins (IκB, Bcl3, p100, and p105). Following different
extracellular stimuli, the IκB proteins are degraded by
26S proteasome, and free and active NF-κB transcription
factors are translocated to the nucleus. Depending on
the dimers formed, distinct sets of genes are transcribed
which results in differed outcomes.
NF-κB is excessively activated in many tumors, stimu-
lating transcription of anti-apoptotic genes and cell cycle
promoters. Nevertheless, the commonly held view that
NF-κB is a pro-tumorigenic stimulator relates to the ca-
nonical tumorigenic p50·p65 heterodimer rather than to
the less common p50·p50 homodimer. p50·p50 was
described as possessing tumor suppressive activities
(Perkins, 2012; Pikarsky and Ben-Neriah, 2006). Further-
more, p50·p50 dimers together with the co-repressor
histone deacetylase 1 (HDAC1) downregulate the tran-
scription of S100A8/9, CXCL1, and CXCL2 chemokines
of neutrophils found in tumor microenvironment. This
repression prevents development of neutrophil-driven
hepatocellular carcinoma (Wilson et al., 2015). In
addition, increased frequency of alkylator-induced muta-
tions was identified in NF-κB1 (−/−) cells and mice.
Moreover, after tumor induction by alkylating agents,
NF-κB1 deficient mice developed more severe lymph-
omas compared to their NF-κB1 (+/+) counterparts
(Voce et al., 2015). In a similar example, NF-κB2-derived
dimers (p52·p52) contribute to the repression of Bcl2,
XIAP, Bcl-XL, Cyclin D1, and c-Myc, leading to cell
cycle arrest and cell death after cell damage (Barre et al.,
2010; Barre and Perkins, 2007).
Conclusions
In our recent study (Kravtsova-Ivantsiv et al., 2015), we
demonstrated that over expression of the NF-κB1 p50
subunit has a strong suppressive effect on glioblastoma
and breast xenograft development. In the same study,
we found one of the missing enzymes in the activation
cascade of NF-κB, KIP1 ubiquitination-promoting com-
plex (KPC). KPC, a heterodimer made of KPC1
(RNF123) and KPC2 (UBAC1), is the ligase that is re-
sponsible for the generation of p50 from p105 both
under basal conditions and following stimulation. RNA
seq analysis of the glioblastoma tumors that overexpress
KPC1 (or p50) revealed significant expression of tumor
suppressors. In addition, functional analysis has shown
alteration of proteins in the tumor interaction with its
microenvironment (e.g., cell adhesion, cell migration,
and cell-cell signaling proteins), all in the direction of
tumor suppression. Analysis of human head and neck
and glioblastoma sections reveled decreased staining of
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KPC1 and nuclear p50 compared to normal tissue. We
hypothesize that one of the critical steps in malignant
transformation may be the downregulation of these pro-
teins that in the normal tissue support the expression of
“beneficial” proteins such as tumor suppressors.
Altogether, we can hypothesize that determination of
the cell outcome can be due, at least partially, to the bal-
ance between NF-κB subunits, and shifting to p50·p50
homodimers is beneficial to cell homeostasis. Further
experiments are needed to substantiate this assumption.
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